Supernus Pharmaceuticals Inc. said a U.S. appeals court upheld a previous patent infringement ruling against TWi Pharmaceuticals Inc. regarding its epilepsy drug.
The U.S. Court of Appeals for the Federal Circuit affirmed the New Jersey District Court's decision that TWi infringed on three Supernus patents related to anti-epileptic drug Oxtellar XR.
The appeals court said the three patents are valid. The decision ends all outstanding litigations and generic challenges to Oxtellar XR.
Rockville, Md.-based Supernus previously won a similar appeals decision against Teva Pharmaceutical Industries Ltd's Actavis.
Supernus said it plans to expand Oxtellar XR's indication to include use as a single therapy for partial seizures of epilepsy as well as the development program for bipolar disorder.
The company holds eight issued patents for Oxtellar XR which will expire in 2027 at the earliest.